All In Biotech

Free tool

FAERS Monitor: Modeyso

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 219876 or its brand name (Modeyso, Dordaviprone Hydrochloride). Reports on generic versions are filed under their own applications.

Reports

129

Serious

97

75% of reports

Hospitalization

27

Death reported

72

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • death60
  • fatigue15
  • disease progression11
  • nausea10
  • neoplasm progression9
  • seizure7
  • vomiting7
  • constipation6
  • hospitalisation6
  • off label use6
  • product dose omission issue6
  • headache5
  • hydrocephalus5
  • muscular weakness5
  • asthenia4

Reports by year received

View as table
YearReports
202530
202699

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,030 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
hydrocephalusSignal5149.863.4597
neoplasm progressionSignal942.222.5323
disease progressionSignal1115.28.6132
deathSignal6011.49.4580
seizureSignal79.94.848
muscular weaknessSignal57.23.021
hospitalisationSignal66.42.922
constipationSignal64.52.113
product dose omission issueSignal63.31.58
fatigueSignal153.12.021
vomitingSignal72.41.25
nauseaSignal102.11.15
asthenia41.70.71
headache51.30.60
off label use61.10.50

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.